Find Locations
For hours, walk-ins and appointments.BCR-ABL1 Transcript Detection for Chronic Myelogenous Leukemia (CML) and Acute Lymphocytic Leukemia (ALL), Quantitative
CPT:
81206; 81207
Synonyms
- Acute Lymphocytic Leukemia, BCR-ABL1 Transcript Detection by RT-PCR, Quantitative
- Chronic Myelogenous Leukemia, BCR-ABL1 Transcript Detection by RT-PCR, Quantitative
- Quantitative BCR-ABL1 Translocation Detection by RT-PCR for CML and ALL
Special Instructions
Please direct any questions regarding this test to oncology customer service at 800-345-4363.
Expected Turnaround Time
5 - 7 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Related Information
Specimen Requirements
Specimen
Whole blood, bone marrow, or cell pellet
Volume
3 to 5 mL whole blood or 1 to 2 mL bone marrow
Minimum Volume
1 mL bone marrow or 3 mL whole blood (Note: This volume does not allow for repeat testing.)
Container
Lavender-top (EDTA) tube, green-top (sodium heparin) tube, yellow-top (ACD-A) tube, tan-top (K2-EDTA) tube or pink-top (K2-EDTA) tube
Collection
Submit at room temperature. Specimens should arrive in the laboratory within 48 hours of collection. Indicate date and time of collection on test request form.
Storage Instructions
Submit at room temperature. If specimen has to be stored more than 48 hours, refrigerate at 2°C to 8°C.
Causes for Rejection
Specimen does not meet collection criteria; frozen whole blood or marrow; leaking tube; clotted blood or marrow; grossly hemolyzed; otherwise visibly degraded; contamination by another specimen; containing suspicious foreign material
Test Details
Use
This assay can detect three different types of BCR-ABL1 fusion transcripts associated with CML, ALL, and AML:e13a2 (previously b2a2) and e14a2 (previously b3a2) (major breakpoint, p210), as well as e1a2 (minor breakpoint, p190). The e13a2 and e14a2 transcript values are titrated to the current International Scale (IS). The standardized baseline is 100% BCR-ABL1 (IS) and major molecular response (MMR) is equivalent to 0.1% BCR-ABL1 (IS) corresponding to a 3-log reduction. Results should be correlated with appropriate clinical and laboratory information as indicated.
Limitations
In vitro studies have indicated that this assay has an analytical detection sensitivity of 4.5 log below the standard baseline (<0.0032%). A negative result does not rule out the presence of low levels of BCR-ABL1 transcript below the level of detection of this assay, or the presence of rare BCR-ABL1 transcripts not detected by the assay.
This test was developed and its performance characteristics determined by Labcorp. It has not been cleared or approved by the Food and Drug Administration.
Methodology
Total RNA is isolated from the sample and subject to a real-time, reverse transcriptase polymerase chain reaction (RT-PCR). The PCR primers and probes are specific for BCR-ABL1 e13a2, e14a2 and e1a2 fusion transcripts. The ABL1 transcript is amplified as the control for cDNA quantity and quality. Serial dilutions of a validated positive control RNA with known t(9;22) BCR-ABL1 are used as reference for quantification of BCR-ABL1 relative to ABL1. The numeric BCR-ABL1 level is reported as % BCR-ABL1/ABL1 and the detection sensitivity is 4.5 log below the standard baseline (<0.0032%).
References
Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Semin Hematol. 2003 Apr; 40(2 Suppl 2):62-68.12783378
NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 2.2017.
White HE, Matejtschuk P, Rigsby P, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 2010 Nov 25; 116(22):e111-117.20720184
LOINC® Map
| Order Code | Order Code Name | Order Loinc | Result Code | Result Code Name | UofM | Result LOINC |
|---|---|---|---|---|---|---|
| 480481 | BCR-ABL1, CML/ALL, PCR, Quant | 52135-1 | 481509 | e13a2 (b2a2) transcript | % | 52130-2 |
| 480481 | BCR-ABL1, CML/ALL, PCR, Quant | 52135-1 | 481510 | e14a2 (b3a2) transcript | % | 52131-0 |
| 480481 | BCR-ABL1, CML/ALL, PCR, Quant | 52135-1 | 481516 | e1a2 transcript | % | 52132-8 |
| 480481 | BCR-ABL1, CML/ALL, PCR, Quant | 52135-1 | 480488 | Interpretation: | N/A | |
| 480481 | BCR-ABL1, CML/ALL, PCR, Quant | 52135-1 | 489031 | Director Review | 72486-4 | |
| 480481 | BCR-ABL1, CML/ALL, PCR, Quant | 52135-1 | 481507 | Background | 77202-0 | |
| 480481 | BCR-ABL1, CML/ALL, PCR, Quant | 52135-1 | 481508 | Methodology | 49549-9 | |
| 480481 | BCR-ABL1, CML/ALL, PCR, Quant | 52135-1 | 511958 | 80563-0 |
© 2021 Laboratory Corporation of America® Holdings and Lexi-Comp Inc. All Rights Reserved.
CPT Statement/Profile Statement
The LOINC® codes are copyright © 1994-2021, Regenstrief Institute, Inc. and the Logical Observation Identifiers Names and Codes (LOINC) Committee. Permission is granted in perpetuity, without payment of license fees or royalties, to use, copy, or distribute the LOINC® codes for any commercial or non-commercial purpose, subject to the terms under the license agreement found at https://loinc.org/license/. Additional information regarding LOINC® codes can be found at LOINC.org, including the LOINC Manual, which can be downloaded at LOINC.org/downloads/files/LOINCManual.pdf